The thing sellers promise most confidently is the thing the longest trial found least durable. In a 60-week double-blind trial, 120 adults with overweight or obesity were randomized 3:2 to semaglutide 2.4 mg or placebo and brought into a laboratory at weeks 0, 20, 40 and 60. At week 20 the treated group reported significantly less past-week hunger (mean difference −17.4 ± 4.8) and significantly less food preoccupation (−14.9 ± 4.5). At weeks 40 and 60, the groups did not differ significantly on appetite outcomes at all — while the same participants ate 291.9, 240.2 and 269.5 kcal less than placebo at those three visits, every one of them significant.[1] The behavior held. The reported quiet did not.
That gap is the reason the term deserves a careful reading rather than a dismissal. Something is being described. What patients report is not the same as feeling full, not the same as the altered flavor perception covered in the taste article, and not the same as disliking food: it is a drop in how often food arrives in the mind uninvited. The question worth answering is whether that description has been converted into a measurement, and what happens to the measurement over a year.
Where the term came from, and how recently
“Food noise” is not a clinical construct that trials adopted. It is a phrase patients used that researchers went back to define. The first scholarly treatment appeared in November 2023, a narrative review written explicitly because anecdotal reports from patients and clinicians on these drugs described less rumination and obsessive preoccupation about food; its contribution was a proposed framework for food cue reactivity, not a measurement.[2] A formal definition followed in 2025: persistent thoughts about food that the individual perceives as unwanted or dysphoric and that may cause social, mental or physical harm, distinguished from ordinary food-related thinking by intensity and intrusiveness, and described as resembling rumination.[3]
That sequence matters for reading a landing page. The term entered marketing before it had a definition, and it had a definition for about eighteen months before anyone published an argument about whether it describes something distinct from what psychology already measured.
It has been measured — twice, both times in 2025
The census here is short and it is the finding. Two instruments exist. The Food Noise Questionnaire was developed and validated in 400 participants, with five items loading onto a single factor, internal consistency of Cronbach α = 0.93 and test-retest reliability of r = 0.79 across a mean of 7.4 days. Convergent validity against two existing preoccupation-with-food questionnaires ran above r = 0.78, and discriminant validity against mood, anxiety and stress measures ran below r = 0.39.[4] The second instrument, the RAID-FN Inventory, was described in mid-2025 as initial work in a paper whose main purpose was to define the term.[3]
One index in that validation runs against the others, and the paper prints it anyway. The five-item model returned a comparative fit index of 0.95 and a standardized root mean squared residual of 0.03 — both comfortably good — alongside a root mean square error of approximation of 0.20, well outside the range usually read as acceptable, on a model with five degrees of freedom.[4] The paper reports all three, concludes the instrument is psychometrically reliable and valid, and states that further work is needed to evaluate clinical utility. Both halves of that belong in any summary of it.
Neither instrument appears as an endpoint in any published randomized trial of a GLP-1 drug. The Food Noise Questionnaire was validated in a general sample, not in people taking these medications, and its own authors state that further research is needed to evaluate its clinical utility.[4] So the sentence a reader needs is this: the phenomenon now has a validated ruler, and nobody has yet measured a GLP-1 drug with it.
The validity number that cuts both ways
The strongest evidence that the questionnaire works is also the strongest evidence that it may be redundant. A correlation above 0.78 with existing preoccupation-with-food scales establishes convergent validity,[4] and it simultaneously means the instrument moves almost in lockstep with measures that predate the term by decades. A 2026 commentary makes exactly that case: that the construct overlaps conceptually with food cue reactivity, food preoccupation, cravings and intrusive food-related cognitions; that evidence on clinical utility remains limited; and that conceptual, methodological and cross-cultural clarity is needed before the term is responsibly integrated into clinical use, partly because of its potential to reclassify a common experience as pathology.[5]
The confidence at the other end of the pipeline is worth pricing against that. A product page describing a drug as quieting food noise is asserting an effect on a construct whose own literature is still arguing about whether it is one thing.
Who built the rulers
Both instruments were developed with commercial weight-management involvement, disclosed in the papers themselves. The Food Noise Questionnaire paper lists four authors who are employees and/or shareholders of WW International.[4] The paper introducing the RAID-FN Inventory names a direct-to-consumer telehealth company inside the instrument’s own acronym, and its disclosure statement records personal payments to the senior author from Roman Health Ventures, LLC, along with institutional support from a list that includes Eli Lilly and WW.[3] None of that invalidates either instrument. It does mean that the measurement of a symptom and the sale of a treatment for it have the same sponsors, which is the kind of thing a reader should know before a clinic asks about their food noise on an intake form — a pattern worth reading alongside the telehealth warning signs.
What the craving trials actually recorded
Craving has been measured on these drugs, with older and well-established instruments, and the short-term results are real. In 72 adults randomized to semaglutide 2.4 mg or placebo for 20 weeks, the Control of Eating Questionnaire indicated better control of eating and fewer and weaker food cravings(P < 0.05), alongside a 35% reduction in ad libitum energy intake and 9.9% weight loss against 0.4% on placebo.[6] In a 30-person crossover trial at 1.0 mg over 12 weeks, participants reported less hunger, fewer food cravings, better control of eating and a lower relative preference for high-fat foods.[7]
Both of those trials were run by the manufacturer, both are short, and both stop at or before the 20-week mark — which is precisely the visit at which the 60-week trial also found a difference, and precisely the horizon past which it stopped finding one.[1] The one measure that did persist beyond 20 weeks in that trial was responsiveness to the rewarding value of food, lower at weeks 20 and 40 by 0.4 ± 0.2 and 0.6 ± 0.2 points — and it, too, is absent from the week-60 readout.[1] The authors’ own conclusion is that reduced energy intake, not sustained subjective relief, is the mechanism that both induces and maintains the weight loss.[1]
What separates the phenomenon from the pitch
Three things are true at once, and a seller usually publishes only the first. Something real is being described: intrusive, unwanted food thoughts are a recognizable experience with a formal definition and a validated five-item questionnaire.[3][4] Something real is being changed: cravings and control of eating measurably improve in the first few months.[6][7] And the durability claim is unsupported: the only trial to ask the question twice more found the subjective difference gone by week 40 while the eating difference remained.[1]
That third fact should change what a reader expects. The loudest benefit reported in the first months is the one least likely to be the reason the weight stays off, which also means its disappearance is not evidence that the drug has stopped working — a different failure mode from the one described in the plateau article. Where intrusive food thoughts sit alongside a diagnosed eating disorder, the evidence is separate and much thinner, and it is collected in the eating disorder history article; where the thoughts are part of a broader mood picture, that record is in the mental health article.
What a compounded vial has to do with any of this
Every craving and preoccupation figure above was produced on FDA-approved semaglutide at labeled doses inside randomized trials. Most sellers covered here dispense compounded semaglutide or tirzepatide, which is not FDA-approved and is not reviewed by the FDA for safety, efficacy or quality before it is dispensed. No trial has measured control of eating, food cravings or food preoccupation on a compounded preparation, and a quieted appetite is not a check on the contents of a vial.
The defensible expectation is narrow. Food-related thinking is likely to get quieter over the first few months, that change is documented on validated craving instruments, it has not been shown to persist at 40 and 60 weeks, and no trial has ever used an instrument built for the term itself. Anything promising a permanent end to food noise is selling a result that has not been measured, in words that entered the literature after they entered the advertising.